Cytiva continues its support for n-Lorem Foundation

  • Donation will assist in the development of antisense oligonucleotide (ASO) medicines to nano-rare disease patients worldwide
  • Third consecutive annual donation, now totaling around $1.4 million

Cytiva has donated approximately $700,000 worth of products and financial support to the n-Lorem Foundation. This is Cytiva’s third year of providing support to the foundation whose mission is to discover and provide experimental antisense oligonucleotide (ASO) medicines to nano-rare disease patients worldwide, offering them life-saving treatments free of charge, for life.

The n-Lorem Foundation is a non-profit organization dedicated to addressing the therapeutic needs of nano-rare disease patients worldwide. These individuals, numbering between one and 30 globally, face the challenge of having no available treatment options due to the extreme rarity of their conditions. The foundation aims to change the treatment landscape for these patients by focusing on the development of experimental ASO medicines.

“We are deeply grateful to Cytiva for their steadfast support and ongoing commitment to the n-Lorem Foundation,” says Stanley T. Crooke, M.D., Ph.D., Founder, CEO and Chairman of n-Lorem Foundation. “Their contributions have been instrumental in our efforts to discover and provide personalized ASO medicines to nano-rare disease patients worldwide. With Cytiva’s support, we can continue to make a profound impact on the lives of these individuals and their families.”

Cytiva’s donation includes essential products such as upstream hardware, cell culture products, and resins. This contribution will assist in the discovery and production of ASO medicines.

Emmanuel Abate, President, Genomic Medicine and Head of Sustainability and Corporate Responsibility, says: “We are thrilled to once again support the n-Lorem Foundation in their pursuit of discovering innovative treatments for nano-rare disease patients. We are committed to helping make a meaningful impact on the lives of patients worldwide, and this donation is a testament to that commitment.”

Learn more about Cytiva’s efforts for Community Impact here and n-Lorem’s mission at

About n-Lorem

n-Lorem Foundation is a non-profit organization established to apply the efficiency, versatility, and specificity of antisense technology to charitably provide experimental antisense oligonucleotide (ASO) medicines to treat nano-rare patients diagnosed with diseases that are the result of a single genetic defect unique to only one or very few individuals. Nano-rare patients describe a very small group of patients (1-30 worldwide) who, because of their small numbers, have few if any treatment options. n-Lorem Foundation was created to provide hope to these nano-rare patients by developing individualized ASO medicines, which are short strands of modified DNA that can specifically target the transcripts of a defective gene to correct the abnormality. The advantage of experimental ASO medicines is that they can be developed rapidly, inexpensively and are highly specific. To date, n-Lorem received over 260 applications for treatment with more than 120 nano-rare patients approved. n-Lorem was founded by Stanley T. Crooke, M.D., Ph.D., former chairman and CEO of Ionis Pharmaceuticals, who founded Ionis Pharmaceuticals in 1989 and, through his vision and leadership, established the company as the leader in RNA-targeted therapeutics. Follow us on TwitterFacebookLinkedIn and YouTube.

To learn more about n-Lorem’s mission at, and please consider giving to n-Lorem to bring hope, possibility and treatment options to these patients and families in need.
About Cytiva

At Cytiva, our mission is to advance and accelerate the development of therapeutics. With nearly 15 000 associates in more than 40 countries, we’re driven to use our expertise and talent to achieve better flexibility, capacity, and efficiency for our customers.  Our broad and deep portfolio of tools and technologies, global scale, and best-in-class service provides critical support from discovery to delivery, for customers spanning researchers, emerging biotech, large-scale biopharma and contract manufacturers.

< | >